Enabling precision medicin for
chronic infections

Need

After antiretroviral treatment againstHIV is initiated, the virus disappearswhile leaving the infected cells intactin a chronic reservoir. This reservoirdetermines the need for medication.Today, the reservoir cannot be monitored. This hampersdevelopment of new drugs and prevents optimal drug usage.

Solution

We provide a service (later a kit) to precisely and sensitively determinethe integration of a foreign DNA sequence in a genome. This can be used for 1) research and drugdevelopment or 2) diagnostics and later 3) precision medicine.

“Through knowledge we reduce HIV-1 stigma and increase an individual’s control over their own infection”

-Peter Svensson, CEO

Market potential

For HIV-1 alone, from a research/drugdevelopment perspecitve the TAM is estimated 1M€/year, from a diagnostic perspective 15B€/year.

Competitive advantages

Sensitive, cost-effective and applicable to routine samples. Studyparticipants do not need to visit clinicbut can measure reservoir fromhome.

Current Status

First patient materials have been analyzed and is being used to optimize the method. First external users (key opinion leaders) are in line to use product after peer-reviewed publication. Funding for initiation of validation study secured through Vinnova.

Partnerships/
Investments or collaborations sought

We are looking to expand our networkand build long-term relations as to accelerate product development and reduce time to market.

Competition

Competing solutions (MIPseq, PRIPseq) can only be used for research and production is not scalable. For routine diagnostics, PCRs and NGS sequencing capture some of the aspects of our solution but not the most important ones, such as reactivation potential of intact HIV.

IPROur

Our underlying CADseq technology is in the process of being patented. Freedom to operate and innovationheight has been assessed.Our team also has a ”knowledgeadvantage”, given extensive experienceand scientific networks.